terminology and guidelines for glaucoma ii - Kwaliteitskoepel

More documents

Recommendations

Info

$Refractiechirurgie - Nederlands Oogheelkundig Gezelschap$

III - ABNORMAL THRESHOLD VISUAL FIELD 1 st EXAM DURING FOLLOW-UP STABLE REPEAT (3-6 months) STAGING EARLY ADVANCED F/U 12 months F/U 6 months NORMAL ABNORMAL BETTER WORSE PROGRESSION OF CATARACT LEARNING EFFECT LOW RELIABILITY BETTER STABLE WORSE CHECK RELIABILITY INDICES NORMAL RELIABILITY FLUCTUATION OF DAMAGE F/U 12 months BETTER F/U 6 months RELIABILITY INDICES LOW REPEAT VF PUPIL SIZE NORMAL SMALLER NO CHANGE CHECK AND CONSIDER Q o L KINETIC PERIMETRY WITH GOLDMANN © European Glaucoma Society FOLLOW-UP STABLE WORSE Be<strong>for</strong>e accepting VF defects as real, they must be cofirmed on two consecutive exams (excluding the initial one). Follow-up intervals are just suggestions. PROGRESSION OF DAMAGE ASSESS RATE OF PROGRESSION CHANGE TREATMENT F/U AS NEEDED
IV - ASSESSMENT AND FOLLOW-UP OPTIC NERVE HEAD VISUAL FIELD NORMAL NORMAL NORMAL ABNORMAL SUSPICIOUS SUSPICIOUS SUSPICIOUS ABNORMAL ABNORMAL IOP < 22 IOP > 21 COUNSEL ARTEFACT OR OTHER CAUSES REPEAT TEST COUNSEL REPEAT TEST COUNSEL EARLY POAG/POAG SUSPECT REPEAT TEST 3-6 MONTHS POAG DAMAGE REPEAT 6-12 MONTHS CONSIDER CCT NORMAL ABNORMAL SUSPICIOUS NORMAL NORMAL SUSPICIOUS ABNORMAL SUSPICIOUS ABNORMAL GLAUCOMA DAMAGE ESTABLISH RATE OF PROGRESSION ESTABLISH TARGET IOP RE-EVALUATE 3-6 months PROGRESSION NO PROGRESSION NEW TARGET IOP FOLLOW-UP 6 months STABLE PROGRESSION RE-EVALUATE 3-12 months NEW TARGET IOP MODIFY RX FOLLOW-UP INTERVALS ARE JUST RECOMMENDATIONS © European Glaucoma Society
Page 2 and 3: ISBN: 88-87434-13-1 Editrice DOGMA
Page 4 and 5: ACKNOWLEDGEMENT This work was made
Page 6 and 7: 2.2.5 - Primary Open-Angle Glaucoma
Page 8 and 9: Foreword These Definitions and Guid
Page 10 and 11: INTRODUCTION The aim of the book is
Page 12 and 13: Since resources are limited worldwi
Page 14 and 15: II - RANDOMIZED CONTROLLED TRIALS F
Page 16 and 17: II.3 - COLLABORATIVE NORMAL TENSION
Page 18 and 19: No stratification for stage of dise
Page 20 and 21: II. 6. 3 - from CNTG 1. Therapy tha
Page 22 and 23: References 1) The Ocular Hypertensi
Page 24 and 25: I - QUESTIONS TO ASK TO YOUR GLAUCO
Page 28 and 29: V - GONIOSCOPIC OPEN ANGLES SOME DI
Page 30 and 31: VII - TREATMENT STEPLADDER JUVENILE
Page 32 and 33: IX - MONOTHERAPY (in alphabetic ord
Page 34 and 35: XI - MANAGEMENT ACUTE ANGLE CLOSURE
Page 36 and 37: XIII - ANTIMETABOLITES FOR WOUND MO
Page 38 and 39: CHAPTER 1 PATIENT EXAMINATION
Page 40 and 41: Other methods 22-25 : Air-puff tono
Page 42 and 43: References 1) Martin XD. Normal int
Page 44 and 45: 1.2 - GONIOSCOPY Gonioscopy is a fu
Page 46 and 47: 1 2 3 4 Fig. 1 Dynamic indentation
Page 48 and 49: The Spaeth classification Insertion
Page 50 and 51: References 1) Palmberg P. Gonioscop
Page 52 and 53: small - size mid - size large - siz
Page 54 and 55: Fig. 5 A) Cirumlinear vessel, B) Ba
Page 56 and 57: 1.3.4.3 - OCT The Optical Coherence
Page 58 and 59: 31) Carpineto P, Ciancaglini M, Zup
Page 60 and 61: central 24 or 30 central degrees re
Page 62 and 63: A retinal sensitivity value worse t
Page 64 and 65: HODAPP CLASSIFICATION 31 EARLY GLAU
Page 66 and 67: References 1) Bengtsson B, Heijl A,
Page 68 and 69: 1.5 - BLOOD FLOW 1.5.1 - VASCULAR F
Page 70 and 71: 28) Flammer J, Orgul S, Costa VP, O
Page 72 and 73: All forms of glaucoma should be cla
Page 74 and 75: 2.2 - PRIMARY OPEN-ANGLE GLAUCOMAS
Page 76 and 77:
2.2.4 - PRIMARY OPEN-ANGLE GLAUCOMA
Page 78 and 79:
2.3 - SECONDARY OPEN-ANGLE GLAUCOMA
Page 80 and 81:
2.3.1.6 - Glaucoma due to intraocul
Page 82 and 83:
2.4 - PRIMARY ANGLE-CLOSURE Primary
Page 84 and 85:
Systemic Risk factors for primary a
Page 86 and 87:
OCCLUDABLE ANGLE: “Occludable”
Page 88 and 89:
2.5.3 - SECONDARY ANGLE-CLOSURE GLA
Page 90 and 91:
CHAPTER 3 TREATMENT PRINCIPLES and
Page 92 and 93:
Furthermore, blindness may occur de
Page 94 and 95:
T A R G E T I O P Target IOP range
Page 96 and 97:
Practical points for topical medica
Page 98 and 99:
3.3.1.1 - Category: ADRENERGIC AGON
Page 100 and 101:
3.3.1.2 - Category: ADRENERGIC ANTA
Page 102 and 103:
3.3.1.3 - Category: CARBONIC ANHYDR
Page 104 and 105:
3.3.1.4 - Category: PARASYMPATHOMIM
Page 106 and 107:
3.3.1.5 - Category: PROSTAGLANDIN D
Page 108 and 109:
Drug interactions Precipitation occ
Page 110 and 111:
COMBINATION THERAPY Starting* Addit
Page 112 and 113:
3.3.2.2 - Category: ADRENERGIC ANTA
Page 114 and 115:
Pregnancy and nursing mothers Only
Page 116 and 117:
3.5 - LASER SURGERY 3.5.1 - LASER I
Page 118 and 119:
3.5.2 - LASER TRABECULOPLASTY 77-89
Page 120 and 121:
3.5.4 - CYCLOPHOTOCOAGULATION Indic
Page 122 and 123:
Although medical therapy is still t
Page 124 and 125:
3.6.4 - COMPLEX CASES Complicated g
Page 126 and 127:
Post-operative use Concentration: 0
Page 128 and 129:
25) Janz NK, Wren PA, Lichter PR, M
Page 130 and 131:
(Rescula TM ) in patients with glau
Page 132 and 133:
in white patients with open-angle g
Page 134 and 135:
CHAPTER 4 TREATMENT GUIDELINES
Page 136 and 137:
4.2 - PRIMARY OPEN-ANGLE GLAUCOMAS
Page 138 and 139:
4.2.7 - OCULAR HYPERTENSION (OH) Al
Page 140 and 141:
4.3.1.7 - Glaucoma associated with
Page 142 and 143:
• Withdrawal of aqueous from vitr
Page 144 and 145:
4.5 - SECONDARY ANGLE-CLOSURE GLAUC
Page 146 and 147:
4.5.3 - SECONDARY ANGLE-CLOSURE GLA
Page 148 and 149:
NOTES
Page 150 and 151:
NOTES
Page 152:
NOTES
show all

terminology and guidelines for glaucoma ii - Kwaliteitskoepel

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?